drugset / Trial / NCT07596381
FAK Inhibitor in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
75 enrolled
InxMed (Shanghai) Co., Ltd.
InxMed (Nanjing) Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is A Phase I/Ib Study，aimed to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Efficacy of Focal Adhesion Kinase Inhibitor IN10028 as Monotherapy and Combination Therapy in Patients with Advanced Solid Tumors.
Timeline
- Start
- 2026-05-30
- Primary completion
- 2027-02-28
- Completion
- 2028-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IN10028 | Unknown | 25 mg | Oral |
| Subject | IN10028 | Unknown | 50 mg | Oral |
| Subject | IN10028 | Unknown | 100 mg | Oral |
| Subject | IN10028 | Unknown | 200 mg | Oral |
| Subject | IN10028 | Unknown | 300 mg | Oral |